Risks of Product Stockpiling Under EU FMD

This document is a guide that outlines the risks associated with product stockpiling in the context of the European Union's Falsified Medicines Directive (EU FMD). It describes how many pharmaceutical manufacturers are unprepared for the serialization of products by the February 9, 2019 deadline, leading some to stockpile non-serialized products. The guide details several risks including unpredictable demand, which can result in lost sales opportunities or excess inventory costs. It also explains the financial implications of holding products in warehouses, such as potential damage, loss, and write-offs due to expired medicines. Additionally, the document discusses the reputational risks that arise when customers perceive a company as unreliable due to limited supply. It emphasizes the urgency for companies to implement serialization solutions and outlines necessary steps such as executing agreements and establishing technical connections to comply with the directive. Finally, it introduces EU FMD Express, a compliance solution designed for smaller manufacturers to manage costs effectively.